Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients

Nephrology

Volumn 20, Issue 4, 2015, Pages 250-256

  Hood, Christopher J ^a,b   Wolley, Martin J ^a,c   Kam, Angela L ^d   Kendrik Jones, Jamie C ^a   Marshall, Mark R ^a,b,e  

^a Counties Manukau District Health Board ^*  (China)

^b Pharmacy Services   (China)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d Baxter Healthcare Pty Ltd   (China)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

haemodialysis; phosphate; phosphate binder

Indexed keywords

CALCIUM; COLESTIPOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; CHELATING AGENT; PHOSPHATE;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; LIPID BLOOD LEVEL; MALE; MAORI (PEOPLE); PACIFIC ISLANDS; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; NEW ZEALAND; ORAL DRUG ADMINISTRATION; PATIENT DROPOUTS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BIOMARKERS; BLOOD COAGULATION; CALCIUM; CHELATING AGENTS; CHOLESTEROL, LDL; COLESTIPOL; FEASIBILITY STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; NEW ZEALAND; PATIENT DROPOUTS; PHOSPHATES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925382538     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12388     Document Type: Article

References (28)

1. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
2. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 520-528.
3. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.
4. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000; 342: 1478-1483.
5. Guérin AP, London GM, Marchais SJ, Metivier F,. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. 2000; 15: 1014-1021.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003; 42: S1-S202.
7. Elder G, Faull R, Branley P, Hawley C, Caring for Australasians with Renal I,. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 2006; 11 (Suppl 1): S230-261.
8. Chen N, Wu X, Ding X, et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: A randomized, double-blind, placebo-controlled, dose-titration study. Nephrol. Dial. Transplant. 2014; 29: 152-160.
9. Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: Results of an open-label 24-month randomized clinical trial. Am. J. Kidney Dis. 2013; 62: 771-778.
10. Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol. Dial. Transplant. 2007; 22: 2856-2866.
11. Wrong O, Harland C,. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiol. 2007; 107: 17-33.
12. Ash S, Campbell K, MacLaughlin H, et al. Evidence based practice guidelines for the nutritional management of chronic kidney disease. Nutr. Diet. 2006; 63: S33-S45.
13. Slatopolsky EA, Burke SK, Dillon MA,. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999; 55: 299-307.
14. Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol. Dial. Transplant. 1998; 13: 2303-2310.
15. Joy MS, Finn WF, Group LAMS,. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. 2003; 42: 96-107.
16. McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ,. Iron-magnesium hydroxycarbonate (fermagate): A novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. CJASN 2009; 4: 401-409.
17. Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014; 86: 638-647.
18. Tentori F, Zhang J, Li Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2012; 27: 4180-4188.
19. Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin. Nephrol. 2004; 62: 104-115.
20. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009; 360: 1395-1407.
21. Shantouf R, Budoff MJ, Ahmadi N, Tiano J, Flores F, Kalantar-Zadeh K,. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am. J. Nephrol. 2008; 28: 275-279.
22. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-1137.
23. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005; 353: 238-248.
24. Chertow GM, Burke SK, Dillon MA, Slatopolsky E,. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol. Dial. Transplant. 1999; 14: 2907-2914.
25. Locatelli F, Spasovski G, Dimkovic N, Wanner C, Dellanna F, Pontoriero G,. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: A 1-year prospective randomized study. Nephrol. Dial. Transplant. 2013; 2014; 29: 1061-1073.
26. Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol. Dial. Transplant. 2014; 29: 1053-1060.
27. Fishbane S, Delmez J, Suki WN, et al. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am. J. Kidney Dis. 2010; 55: 307-315.
28. Tsang RC, Roginsky MS, Mellies MJ, Glueck CJ,. Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving colestipol resin. Pediatr. Res. 1978; 12: 980-982.